September August July June May April March February January
Wednesday, March 22, 2017
Cancer Therapy Advisor (3/21, Primeau) reports that research indicated “ultrasound findings at mid-neoadjuvant (NAC) treatment of breast cancer were associated with residual cancer burden (RCB) among patients with triple-negative breast cancer (TNBC) and hormone receptor (HR)-negative, HER2-positive disease.” The findings were published in The Oncologist.
Categories: 2017, March, News, Research and CareNumber of views: 8864
Tags: